- Home
- NCNA vs PALI Comparison
NCNA vs PALI Comparison
Compare NCNA & PALI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NCNA | PALI |
|---|---|---|
| Founded | 1997 | 1996 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.6M | 268.6M |
| IPO Year | 2017 | N/A |
Fundamental Metrics
Financial Performance| Metric | NCNA | PALI |
|---|---|---|
| Price | $3.84 | $2.03 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | 68.4K | ★ 4.7M |
| Earning Date | 11-13-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.78 | $0.53 |
| 52 Week High | $330.00 | $3.30 |
Technical Indicators
Market Signals| Indicator | NCNA | PALI |
|---|---|---|
| Relative Strength Index (RSI) | 47.20 | 52.70 |
| Support Level | $4.10 | $1.73 |
| Resistance Level | $4.55 | $2.27 |
| Average True Range (ATR) | 0.29 | 0.19 |
| MACD | 0.03 | -0.00 |
| Stochastic Oscillator | 37.14 | 57.01 |
Price Performance
Historical ComparisonAbout NCNA NuCana plc
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.
About PALI Palisade Bio Inc.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.